Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 27T51 |
Synonyms | |
Therapy Description |
Limited information is currently available on 27T51, a putative chimeric antigen receptor (CAR)-T cell therapy targeting MUC16 (Jul 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
27T51 | 27T-51|27T 51 | MUC16 Targeted Therapy 10 | Limited information is currently available on 27T51, a putative chimeric antigen receptor (CAR)-T cell therapy targeting MUC16 (Jul 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06469281 | Phase I | 27T51 27T51 + Bevacizumab + Cemiplimab 27T51 + Cemiplimab | A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers | Recruiting | USA | 0 |